These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3555385)

  • 41. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 42. A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
    Haslam MT; Bromham BM; Schiff AA
    Acta Psychiatr Scand; 1975 Feb; 51(2):92-100. PubMed ID: 1091124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial.
    Siris SG; Morgan V; Fagerstrom R; Rifkin A; Cooper TB
    Arch Gen Psychiatry; 1987 Jun; 44(6):533-9. PubMed ID: 3555386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B; Palmstierna T
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.
    Hogarty GE; McEvoy JP; Munetz M; DiBarry AL; Bartone P; Cather R; Cooley SJ; Ulrich RF; Carter M; Madonia MJ
    Arch Gen Psychiatry; 1988 Sep; 45(9):797-805. PubMed ID: 3415422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dysphoric syndrome in schizophrenia and its implications for relapse.
    Hirsch SR; Jolley AG
    Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
    [No Abstract]   [Full Text] [Related]  

  • 49. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ; Saxena B; Foley P; Grof P
    Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of 6- with 9-week trials of adjunctive imipramine in postpsychotic depression.
    Siris SG; Adan F; Strahan A; Aronson A; Mandeli J; Fasano-Dube B
    Compr Psychiatry; 1989; 30(6):483-8. PubMed ID: 2582754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
    Knights A; Okasha MS; Salih MA; Hirsch SR
    Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tardive oculogyric crisis and obsessional thoughts.
    Sachdev P
    Br J Psychiatry; 1991 May; 158():720-1. PubMed ID: 1860035
    [No Abstract]   [Full Text] [Related]  

  • 57. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
    Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
    Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.